Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-007-9369-9
Annals of Surgical Oncology 14:2141-2149 (2007)
© 2007 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, S.
Right arrow Articles by Monden, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, S.
Right arrow Articles by Monden, M.

Original Article

Expression Level of Hepatoma-Derived Growth Factor Correlates with Tumor Recurrence of Esophageal Carcinoma

Shinji Yamamoto, MD, PhD1, Yasuhiko Tomita, MD, PhD2, Yoshihiko Hoshida, MD, PhD2, Eiichi Morii, MD, PhD2, Takushi Yasuda, MD, PhD1, Yuichiro Doki, MD, PhD1, Katsuyuki Aozasa, MD, PhD2, Hirokazu Uyama, MD, PhD3, Hideji Nakamura, MD, PhD4 and Morito Monden, MD, PhD1

1 Department of Surgery, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan 5650871
2 Department of Pathology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 5650871, Japan
3 Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan 5650871
4 Division of Hepatobiliary and Pancreatic Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1, Mukogawacho, Nishinomiya, Hyogo, Japan 6638501

Correspondence: Address correspondence and reprint requests to: Shinji Yamamoto, MD, PhD; E-mail: shinjiyamamoto2005{at}yahoo.co.jp

Background: Hepatoma-derived growth factor (HDGF) is thought to play an important role in the development and progression of carcinomas. In the present study, association of HDGF expression with recurrence and prognosis of esophageal carcinoma (EC) was examined.

Methods: HDGF expression in 111 patients with EC (101 men and 10 women) with ages ranging from 38 to 82 (median, 61) years was analyzed by immunohistochemistry. Samples in which >90% of tumor cells exhibited nuclear and cytoplasmic HDGF immunoreactivity at levels greater than or equal to what is observed in the endothelial cells were regarded as HDGF expression level 1, and others as HDGF expression level 0.

Results: Thirty-seven of 111 patients showed level 1 HDGF expression. There was no correlation between HDGF expression and other clinicopathologic factors. Patients with level 1 expression showed poorer disease-free and overall survival (P < .05 for both) compared with those with level 0 expression. HDGF expression was an independent prognostic factor for patients with early (pT1–2) stage of the disease, but not for those with advanced (pT3–4) stage.

Conclusions: HDGF expression level was shown to be a prognostic factor for EC.

Key Words: HDGF • Hepatoma-derived growth factor • Esophageal carcinoma • Immunohistochemistry






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society of Surgical Oncology.